High-dose cyclophosphamide–irinotecan–vincristine for primary refractory neuroblastoma
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference38 articles.
1. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study;Saylors;J Clin Oncol,2001
2. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma;Garaventa;Cancer,2003
3. Park JR, Stewart CF, London WB, et al. A topotecan-containing induction regimen for treatment of high risk neuroblastoma. Proc Am Soc Clin Oncol 2006 abstract #9013.
4. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma: results of a phase-II trial;Simon;J Cancer Res Clin Oncol,2007
5. Cheung N-KV: five-day courses of irinotecan as palliative therapy for patients with neuroblastoma;Kushner;Cancer,2004
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Stage 4N neuroblastoma before and during the era of anti‐GD2 immunotherapy;International Journal of Cancer;2023-08-21
2. High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma;Pediatric Blood & Cancer;2023-04-17
3. Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting;Cancer;2022-09-13
4. Immunotherapy with anti‐G D2 monoclonal antibody in infants with high‐risk neuroblastoma;International Journal of Cancer;2022-08-17
5. Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma;Frontiers in Oncology;2022-03-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3